STABIL-study: The Course of Therapy, Safety and Pharmacokinetic Parameters of Conversion of Prograf® to Tacrolimus HEXAL®/Crilomus® in Renal Transplant Recipients - an Observational Study in Germany.
Lukas J LehnerKlaus KalbKarl WeigandUlrich PeinPeter SchenkerWolfgang SeegerRobert RoehleKerstin DienesFabian HalleckKlemens BuddePublished in: Current reviews in clinical and experimental pharmacology (2022)
In conclusion, conversion to the generic tacrolimus formulation can be considered safe and feasible in long-term kidney transplant recipients in Germany. As suggested by guidelines, vigilant therapeutic drug monitoring is recommended to account for possible tacrolimus concentration variability on the individual patient level.